Inhibitors of extracellular Hsp90

Details Inhibitors of extracellular Hsp90 Inhibitors of extracellular Hsp90

2011-06-14

2011-06-14

Reddig, Peter J (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S138100, C424S141100, C424S155100, C424S174100, C435S007100, C435S007230, C435S007920, C435S007940, C530S387100, C530S387700, C530S388100, C530S388800

Reexamination Certificate

active

07959915

ABSTRACT:
The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells.

REFERENCES:
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5541077 (1996-07-01), Burnie et al.
patent: 5777083 (1998-07-01), Burnie et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2008/0038267 (2008-02-01), Burnie et al.
patent: 0406029 (1995-03-01), None
patent: 91/00351 (1991-01-01), None
patent: 94/04676 (1994-03-01), None
patent: 2000/53169 (2000-09-01), None
patent: WO 2000/053169 (2000-09-01), None
patent: 01/76627 (2001-10-01), None
patent: WO 02/15925 (2002-02-01), None
patent: WO 2002/015925 (2002-02-01), None
patent: 2006/03384 (2006-12-01), None
patent: 2007/77454 (2007-12-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Zellner et al (Clin. Can. Res., 1998, 4:1797-17802).
Zips et al (In vivo, 2005, 19:1-7).
Gura (Science, 1997, 278:1041-1042).
Kaiser (Science, 2006, 313, 1370).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Conroy et al. (European J. Cancer, 1998. 34:942-943).
Byers, T. (CA Journal, vol. 49, No. 6, Nov./Dec. 1999).
Cotterchio et al, 2000, Chronic Diseases in Canada, (Electronic Version downloaded from www.phac-aspc.gc.ca/publicat/cdic-mcc/21-2/f—e.html).
Martin et al (Journal of the National Cancer Institute, 92:1126-1135).
Eustace et al. (Nature Cell Biology, Jun. 2004, 6:507-514).
Taber's Cyclopedic Medical Dictionary (1985, F.A. Davis Company, Philadelphia, p. 274).
Busken, C et al, (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850).
Kaiser (Science, 2006, 313: 1370).
Krontiris and Capizzi (Internal Medicine, 4th Edition, Editor-in-chief Jay Stein, Elsevier Science, 1994 Chapters 71-72, pp. 699-729).
Carter, S. K. et al. Chemotherapy of Cancer; Second edition; John Wiley & Sons: New York, 1981; appendix C.
Janeway et al. (Immunobiology 5, 2001, p. 100-101).
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79: 1979-1983).
Bowie et al. (Science, 247:1306-1310, 1990).
Gussow et al. (1991, Methods in Enzymology 203:99-121).
MacCallum et al. (J. Mol. Biol. (1996) 262, 732-745).
Casset et al. (BBRC 2003 307:198-205).
Wu et al. (J. Mol. Biol. (1999) 294, 151-162).
Stellas et al. (FEBS J. 2008 275 (Suppl. 1): 345).
Neckers L. et al., “Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.” Invest New Drugs. 1999;17(4):361-73.
Chiosis G et al., “Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation Her2 tyrosine kinase.” Bioorg Med Chem. Nov. 2002;10(11):3555-64.
Ferrarini M et al., “Unusual expression and localization of heat-shock proteins in human tumor cells.” Int J Cancer Jun. 19, 1992;51(4):613-9.
Marcu MG et al., “Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.” J Natl Cancer Inst. Feb. 2, 2000;92(3):242-8.
Drolet DW et al., “A high throughout platform for systematic evolution of ligands by exponential enrichment (SELEX).” Comb Chem High Throughput Screen. Oct. 1999;2(5)271-8.
Becker, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Experimental Dermatology. 2004; 13(1):27-32.
Nemoto T. , et al., Domain structures and immunogenic regions of the 90kDa heat-shock protein (Hsp90). Probing with a library of anti-Hsp90 monoclonal antibodies and limited proteolysis, JBC., 1997, 272; 42: 26179-87.
Yoshihiko Miyata, Molecular chaperone HSP90 as a novel cancer target for cancer chemotherapy; Folio Pharmacol., Japan (Nihon Yakurigaku Zasshi), Jan 2003, vol, 121, No. 1, pp. 33-42.
Stellas D., et al., Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin. Cancer Res., 2007; 13(6):18311838.
Stellas D., et al., Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biology, 2010, 11:51.
Tsutsumi, et al., A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. 2008; Oncogene 27: 2478-2487.

Affiliated with

Also associated with

Rating

Inhibitors of extracellular Hsp90 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of extracellular Hsp90, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of extracellular Hsp90 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2720477